Actively Recruiting
Randomized Phase II Study Comparing Ramucirumab Plus Paclitaxel Versus FOLFIRI Chemotherapy in Advanced Small Bowel Adenocarcinoma
Led by SWOG Cancer Research Network · Updated on 2026-10-23
94
Participants Needed
536
Research Sites
25 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness of two treatment regimens involving ramucirumab combined with paclitaxel or the FOLFIRI regimen leucovorin calcium, fluorouracil, and irinotecan hydrochloride in patients with advanced or treatment-resistant small bowel adenocarcinoma. This phase II randomized study aims to determine which regimen better controls disease progression and assess overall response, survival, and safety. The study also explores how changes in CEA levels may relate to treatment outcomes and collects tissue and blood samples for future research. Participants are randomly assigned to one of two treatment groups. In the first group, patients receive ramucirumab intravenously on days 1 and 15 and paclitaxel intravenously on days 1, 8, and 15 of each 28-day cycle. In the second group, patients receive irinotecan and leucovorin intravenously on days 1 and 15, with fluorouracil given as an intravenous bolus on days 1 and 15 and continuous infusion over days 1-3 and 15-17. Treatment cycles repeat every 28 days until disease progression or unacceptable side effects occur. After treatment ends, participants are followed every 8 weeks until disease progression and then every 6 months for up to three years. During the study, participants undergo evaluations including tumor assessments within specific time frames before starting treatment. Researchers monitor progression-free survival, overall survival, treatment response, and adverse events up to three years after registration. Regular follow-up visits assess health status and disease progression. Participants provide medical history, physical exams, and laboratory tests before enrollment, and specimen banking is offered for additional research. This comprehensive monitoring helps evaluate the safety and effectiveness of the treatments over time.
CONDITIONS
Brief Title
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Research Team
C
Christy Klepetko
D
Dana Sparks
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here